FMP
ALPS Medical Breakthroughs ETF
SBIO
AMEX
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
31.86 USD
-0.3751 (-1.18%)
About
ceo
N/A
sector
Financial Services
industry
Asset Management
website
N/A
exchange
AMEX
Description
The fund employs a "passive management" - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
CIK
0001414040
ISIN
US00162Q5936
CUSIP
00162Q593
Address
N/A
Phone
NA
Country
US
Employee
N/A
IPO Date
Dec 31, 2014
Summary
ISIN
US00162Q5936
Exchange
AMEX
Beta
0.83
Market Cap
114.14M
52-Week
23.21-38.8
Volume Avg.
13.33k
Price
31.86
Country
US
Management Assets
-
Total Holdings
-
NAV
-
NAV Currency
-
Historical Prices
We are unable to load the chart at this time.
Sector Weightings
We are unable to load the chart at this time.
Country Weightings
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SBIO News
It looks like there's no news available.
